Valued at USD 2.80 billion in 2020, the contrast media market is projected to reach USD 5.33 billion by 2028, growing at a CAGR of 8.6% during the forecast period 2021–2028, according to Polaris Market Research. Newer modalities and technology-led product launches are expanding the competitive field. Key players include Lantheus Medical Imaging, Inc., Bayer AG, General Electric, Nano Therapeutics Pvt. Ltd., Guerbet, Bracco Diagnostic, Inc., iMax, and Trivitron Healthcare.

MRI Growth and Gadolinium-Based Contrast Agents

MRI and ultrasound are two of the three modalities in the report's segmentation, and the MRI segment is projected to witness lucrative growth over the assessment period. During MRI, contrast media reduce the relaxation time of cells within tissues to modify contrast and produce an image. Gadolinium-based contrast agents are the most frequently used in MRI. The report explains that gadolinium has a 3+ oxidation state and 7 unpaired electrons, causing surrounding water to relax quickly and enhancing image quality, and that it is extensively used to distinguish normal from malignant tissue.

Microbubble Agents and Ultrasound

Microbubble contrast agents are expected to witness a lucrative growth rate over the assessment period. Their smaller size and ability to reflect ultrasound waves to a high degree of echogenicity are cited as reasons for rising demand. Contrast-enhanced ultrasound is described as a cheaper alternative for visualizing blood flow without the use of lethal rays, and these media are mostly useful in patients with kidney disorders.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/contrast-media-contrast-agents-market

AI-Powered Delivery Technology

In April 2024, GE Healthcare introduced a new AI-powered contrast media injection system. The system is intended to enhance image quality and lower the risk of contrast-induced nephropathy by optimizing contrast dose and timing for customized imaging protocols. The launch indicates that competition is extending from the agents themselves to the technology used to deliver them.

New Agent Launches and Approvals

The report states that companies are introducing new contrast agents to diversify their offerings. Bracco Diagnostics introduced Gadoteridol to image neck and head lesions using MRI, and GE Healthcare previously introduced Clariscan in the European region. In October 2023, Guerbet received marketing authorization for Elucirem (Gadopiclenol) from the European Commission. These launches reflect a competitive environment in which, according to the report's Porter's Five Forces outline, rivalry among existing firms is high, the bargaining power of suppliers and buyers is moderate, and the threat of new entrants is low.

Application and Regional Context

Applications span cardiovascular disorders, neurological disorders, gastrointestinal disorders, cancer, nephrological disorders, musculoskeletal disorders, and others. North America held a dominant share of the global market in 2020, supported by well-established hospital facilities with equipped diagnostic equipment and patient awareness of early diagnosis for cancer, rare diseases, and hereditary disorders.

The report also covers Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria), Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea), Latin America (Brazil, Mexico, Argentina), and the Middle East and Africa (Saudi Arabia, UAE, Israel, South Africa).

Market Dynamics

The report outlines growth drivers including the rising prevalence of targeted diseases and the ageing population, while product recalls are identified as a restraint. Rising imaging test volumes linked to complex chronic conditions continue to support overall demand for contrast agents. The report's segmentation framework spans product, modality, application, and geographic region, with country-level detail for markets such as the U.S., Canada, and the UK.

Outlook for Manufacturers and Providers

As the contrast media market moves from USD 2.80 billion in 2020 toward USD 5.33 billion by 2028, MRI, ultrasound, and AI-assisted delivery are the areas the report flags for growth and innovation. Manufacturers that diversify portfolios and engage with regulators, as Guerbet did in Europe, are positioned to capture emerging demand. The report was published in April 2021 with a 2020 base year and historical data for 2016–2019.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market